Tacrine hydrochloride treatment IND: Methods for rapid physician and patient enrolment and data retrieval

James P. Symons, Michael Ibara, D. Kraemer, Faye A. Luscombe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A Treatment IND (TIND) is a mechanism available to the Food and Drug Administration (FDA) in the United States by which promising new drugs can be provided to patients with life-threatening illnesses. In many instances, the illness is life-threatening but of relatively low incidence, making the demand for the new treatment limited. However, if the disease is more prevalent and incidence is increasing, the demand for access to an experimental therapy may be substantially greater. Novel approaches and technologies would help manage recruitment of physicians, enrolment of patients and retrieval and timely analysis of data. Such was the case in the TIND for tacrine hydrochloride (Cognex®), a cholinesterase inhibitor which was under development for the treatment of patients with Alzheimer's Disease (AD). There were an estimated 4 million prevalent cases of AD in the US for which no approved therapeutic option was available at the time this TIND was initiated. We anticipated that there could be a large demand by both physicians and patients to enrol in the TIND. Therefore, to meet this demand, various mechanisms were employed to allow rapid enrolment and drug shipments to the patient. In addition, physicians who participated in the TIND were able to use a telephone touch-tone data entry system for reporting data and ordering new supplies of tacrine for their patients. Serious adverse events were reported directly to trained operators and summarized on a weekly basis for reporting to the FDA. At the time the programme was terminated, nearly 2000 physicians had enrolled to participate in the TIND and nearly 10,000 patients had received tacrine under the programme. The methods employed in this study to collect clinic visit and safety data met both regulatory and good clinical practice guidelines. In summary, a large volume of data was handled rapidly and efficiently in this programme.

Original languageEnglish
Pages (from-to)409-416
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume6
Issue number6
DOIs
Publication statusPublished - Nov 1997

Fingerprint

Tacrine
Information Storage and Retrieval
Physicians
Therapeutics
United States Food and Drug Administration
Alzheimer Disease
Investigational Therapies
Cholinesterase Inhibitors
Incidence
Touch
Ambulatory Care
Practice Guidelines
Telephone
Information Systems
Pharmaceutical Preparations
Research Design
Technology
Safety

Keywords

  • Alzheimer's disease
  • Tacrine
  • Touch-tone data entry
  • Treatment IND

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Tacrine hydrochloride treatment IND : Methods for rapid physician and patient enrolment and data retrieval. / Symons, James P.; Ibara, Michael; Kraemer, D.; Luscombe, Faye A.

In: Pharmacoepidemiology and Drug Safety, Vol. 6, No. 6, 11.1997, p. 409-416.

Research output: Contribution to journalArticle

@article{5c5285f6bc4f4f4a8f82e6e7fce7f21d,
title = "Tacrine hydrochloride treatment IND: Methods for rapid physician and patient enrolment and data retrieval",
abstract = "A Treatment IND (TIND) is a mechanism available to the Food and Drug Administration (FDA) in the United States by which promising new drugs can be provided to patients with life-threatening illnesses. In many instances, the illness is life-threatening but of relatively low incidence, making the demand for the new treatment limited. However, if the disease is more prevalent and incidence is increasing, the demand for access to an experimental therapy may be substantially greater. Novel approaches and technologies would help manage recruitment of physicians, enrolment of patients and retrieval and timely analysis of data. Such was the case in the TIND for tacrine hydrochloride (Cognex{\circledR}), a cholinesterase inhibitor which was under development for the treatment of patients with Alzheimer's Disease (AD). There were an estimated 4 million prevalent cases of AD in the US for which no approved therapeutic option was available at the time this TIND was initiated. We anticipated that there could be a large demand by both physicians and patients to enrol in the TIND. Therefore, to meet this demand, various mechanisms were employed to allow rapid enrolment and drug shipments to the patient. In addition, physicians who participated in the TIND were able to use a telephone touch-tone data entry system for reporting data and ordering new supplies of tacrine for their patients. Serious adverse events were reported directly to trained operators and summarized on a weekly basis for reporting to the FDA. At the time the programme was terminated, nearly 2000 physicians had enrolled to participate in the TIND and nearly 10,000 patients had received tacrine under the programme. The methods employed in this study to collect clinic visit and safety data met both regulatory and good clinical practice guidelines. In summary, a large volume of data was handled rapidly and efficiently in this programme.",
keywords = "Alzheimer's disease, Tacrine, Touch-tone data entry, Treatment IND",
author = "Symons, {James P.} and Michael Ibara and D. Kraemer and Luscombe, {Faye A.}",
year = "1997",
month = "11",
doi = "10.1002/(SICI)1099-1557(199711/12)6:6<409::AID-PDS278>3.0.CO;2-H",
language = "English",
volume = "6",
pages = "409--416",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Tacrine hydrochloride treatment IND

T2 - Methods for rapid physician and patient enrolment and data retrieval

AU - Symons, James P.

AU - Ibara, Michael

AU - Kraemer, D.

AU - Luscombe, Faye A.

PY - 1997/11

Y1 - 1997/11

N2 - A Treatment IND (TIND) is a mechanism available to the Food and Drug Administration (FDA) in the United States by which promising new drugs can be provided to patients with life-threatening illnesses. In many instances, the illness is life-threatening but of relatively low incidence, making the demand for the new treatment limited. However, if the disease is more prevalent and incidence is increasing, the demand for access to an experimental therapy may be substantially greater. Novel approaches and technologies would help manage recruitment of physicians, enrolment of patients and retrieval and timely analysis of data. Such was the case in the TIND for tacrine hydrochloride (Cognex®), a cholinesterase inhibitor which was under development for the treatment of patients with Alzheimer's Disease (AD). There were an estimated 4 million prevalent cases of AD in the US for which no approved therapeutic option was available at the time this TIND was initiated. We anticipated that there could be a large demand by both physicians and patients to enrol in the TIND. Therefore, to meet this demand, various mechanisms were employed to allow rapid enrolment and drug shipments to the patient. In addition, physicians who participated in the TIND were able to use a telephone touch-tone data entry system for reporting data and ordering new supplies of tacrine for their patients. Serious adverse events were reported directly to trained operators and summarized on a weekly basis for reporting to the FDA. At the time the programme was terminated, nearly 2000 physicians had enrolled to participate in the TIND and nearly 10,000 patients had received tacrine under the programme. The methods employed in this study to collect clinic visit and safety data met both regulatory and good clinical practice guidelines. In summary, a large volume of data was handled rapidly and efficiently in this programme.

AB - A Treatment IND (TIND) is a mechanism available to the Food and Drug Administration (FDA) in the United States by which promising new drugs can be provided to patients with life-threatening illnesses. In many instances, the illness is life-threatening but of relatively low incidence, making the demand for the new treatment limited. However, if the disease is more prevalent and incidence is increasing, the demand for access to an experimental therapy may be substantially greater. Novel approaches and technologies would help manage recruitment of physicians, enrolment of patients and retrieval and timely analysis of data. Such was the case in the TIND for tacrine hydrochloride (Cognex®), a cholinesterase inhibitor which was under development for the treatment of patients with Alzheimer's Disease (AD). There were an estimated 4 million prevalent cases of AD in the US for which no approved therapeutic option was available at the time this TIND was initiated. We anticipated that there could be a large demand by both physicians and patients to enrol in the TIND. Therefore, to meet this demand, various mechanisms were employed to allow rapid enrolment and drug shipments to the patient. In addition, physicians who participated in the TIND were able to use a telephone touch-tone data entry system for reporting data and ordering new supplies of tacrine for their patients. Serious adverse events were reported directly to trained operators and summarized on a weekly basis for reporting to the FDA. At the time the programme was terminated, nearly 2000 physicians had enrolled to participate in the TIND and nearly 10,000 patients had received tacrine under the programme. The methods employed in this study to collect clinic visit and safety data met both regulatory and good clinical practice guidelines. In summary, a large volume of data was handled rapidly and efficiently in this programme.

KW - Alzheimer's disease

KW - Tacrine

KW - Touch-tone data entry

KW - Treatment IND

UR - http://www.scopus.com/inward/record.url?scp=0031455920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031455920&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-1557(199711/12)6:6<409::AID-PDS278>3.0.CO;2-H

DO - 10.1002/(SICI)1099-1557(199711/12)6:6<409::AID-PDS278>3.0.CO;2-H

M3 - Article

C2 - 15073761

AN - SCOPUS:0031455920

VL - 6

SP - 409

EP - 416

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 6

ER -